A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma

A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive Glioblastoma

This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single intratumoral (IT) injection of C5252 in patients with recurrent or progressive glioblastoma (GBM).

Study Overview

• Status: Not yet recruiting
• Conditions: Glioblastoma; Solid Tumor; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain
• Intervention / Treatment: Biological: C5252

Detailed Description

This is a Phase 1 open label, first in human study of C5252 monotherapy designed to determine the safety and tolerability of a single IT injection of C5252 in patients with recurrent or progressive GBM. The Part 1 portion of the study is a 3+3 design to evaluate escalating doses of C5252. Total enrollment will depend on the toxicities and/or activity observed, with approximately 36 evaluable participants enrolled. Once the recommended dose (RD) is identified from Part 1, Part 2 Dose Expansion will enroll up to 15 additional participants to further assess the safety, tolerability, and preliminary efficacy of a single IT injection of C5252 monotherapy.

• Study Type: Interventional
• Enrollment (Anticipated): 51
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: ImmVira Pharma Co., LTD; Phone Number: 781-718-5121; Email: clinicaltrials@immviragroup.com

Study Locations

• United States
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • Huntsman Cancer Institute
      • Contact: Randy Jensen, MD; Email: clinicaltrials@immviragroup.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

1. Signed and dated approved informed consent form (ICF) before any protocol-directed screening procedures are performed.
2. Participants must have histopathologically confirmed recurrent supratentorial glioblastoma.
3. Participants must have progressed after at least 1 line but no more than 2 lines of therapy.
4. Evidence of progression by RANO criteria based on MRI scan.
5. Residual lesion must be ≥ 1.0 cm and < 5.5 cm contrast-enhancing in diameter as determined by MRI.
6. Age ≥ 18 years.
7. Karnofsky Performance Score (KPS) ≥ 70.
8. Life expectancy > 12 weeks.
9. Participants must have normal organ and marrow function.
10. Participants must commit to the use of a reliable method of birth control.
11. Resolution of all AEs due to previous therapies to ≤ Grade 1 or baseline.
12. Capable of understanding and complying with protocol requirements.

Key Exclusion Criteria:

1. Inability to undergo MRI examination for any reason.
2. A contrast-enhancing brain tumor that does not meet protocol criteria.
3. Prior history of encephalitis, multiple sclerosis, or other CNS infection.
4. Clinical diagnosis of Li-Fraumeni Syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways.
5. Required steroid increase within 2 weeks prior to date of C5252 administration.
6. Systemic therapy with immunosuppressive agents within 28 days prior to date of C5252 administration.
7. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any other medical condition that precludes surgery. Also, psychiatric illness/social situations that would limit compliance with study requirements.
8. Bleeding diathesis, or requirement for anticoagulants, or antiplatelet agents, including NSAIDs that cannot be stopped for surgery or biopsy.
9. Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin.
10. Requires continued concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir).
11. Pregnant or lactating.
12. Prior organ transplantation.
13. Active hepatitis B virus, hepatitis C virus, or a positive serological test at Screening.
14. Active oral herpes lesion at Screening.
15. Congestive heart failure (> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest), or clinically significant cardiac arrhythmias.
16. History of allergic reactions attributed to compounds of similar biological composition to HSV-1, IL-12, or anti-PD-1 monoclonal antibody.
17. Active infection with SARS-CoV-2 virus.
18. Other systemic conditions or organ abnormalities that, in the opinion of the Investigator, may interfere with the conduct and/or interpretation of the current study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1: Dose Escalation; C5252 single agent dose escalation in participants with glioblastoma	Biological: C5252; A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
Experimental: Part 2: Dose Expansion; Recommended dose of C5252 as determined in Part 1 Dose Escalation in participants with glioblastoma	Biological: C5252; A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the safety and tolerability of C5252	Number of participants in dose escalating cohorts with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.	Up to 28 days from C5252 injection
Characterize Dose Limiting Toxicities	Incidence of DLTs	Up to 28 days from C5252 injection
Identify the maximum tolerated dose (MTD) and/or the RD of C5252	Incidence of DLTs	Up to 28 days from C5252 injection

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the PK of C5252	Measure anti-PD-1 antibody concentration in blood using Anti-PD-1 antibody ELISA test and IL-12 concentration in blood using IL-12p70 ELISA test.	Up to 2 years from C5252 injection
Evaluate the viral shedding of C5252	Measure viral shedding of C5252 after intratumoral injection in saliva, nasopharyngeal mucus, and urine using qPCR (quantitative polymerase chain reaction) test.	Up to 2 years from C5252 injection
Overall response rate (ORR)	ORR is defined as the proportion of participants who have had a partial response (PR), or complete response (CR) to intervention, based on Investigator Assessment for Neuro-oncology (RANO).	Up to 2 years from C5252 injection
Progression-free survival (PFS)	PFS is defined as the time from Day 1 to the first documentation of progressive disease (PD) or death from any cause, whichever occurs first per RANO.	Up to 2 years from C5252 injection
Overall Survival (OS)	OS is defined as the time from enrollment to death from any cause.	Up to 2 years from C5252 injection

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate blood cytokines	Measure blood cytokines using MSD V-Plex Electrochemiluminescence Immunoassay test.	Up to 28 days from C5252 injection
Evaluate lymphocyte profiling	Conduct lymphocyte profiling using PBMC Flow cytometry test.	Up to 28 days from C5252 injection

Collaborators and Investigators

• Sponsor: ImmVira Pharma Co. Ltd

Study record dates

Study Major Dates

• Study Start (Anticipated): March 15, 2023
• Primary Completion (Anticipated): April 30, 2023
• Study Completion (Anticipated): April 30, 2026

Study Registration Dates

• First Submitted: September 15, 2021
• First Submitted That Met QC Criteria: October 14, 2021
• First Posted (Actual): October 27, 2021

Study Record Updates

• Last Update Posted (Actual): October 12, 2022
• Last Update Submitted That Met QC Criteria: October 9, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioblastoma
• Other Study ID Numbers: MVR-C5252-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No